The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis

Autoimmunity Reviews

Volumn 11, Issue 5, 2012, Pages 315-320

  Fabris, Martina ^a   Quartuccio, Luca ^a   Lombardi, Sandra ^a   Saracco, Marta ^b   Atzeni, Fabiola ^c   Carletto, Antonio ^d   Cimmino, Marco ^e   Fabro, Cinzia ^a   Pontarini, Elena ^a   Pellerito, Raffaele ^b   Bambara, Lisa Maria ^d   Sarzi Puttini, Piercarlo ^c   Cutolo, Maurizio ^e   Manfredi, Mariangela ^f   Benucci, Maurizio ^f   Morassi, Pia ^g   Fischetti, Fabio ^g   Padovan, Melissa ^h   Govoni, Marcello ^h   Curcio, Francesco ^a   Tonutti, Elio ^a   De Vita, Salvatore ^a   more..

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f New Hospital San Giovanni di Dio   (Italy)

^g UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^h UNIVERSITY OF FERRARA   (Italy)

Author keywords

IL 6; Pharmacogenetics; Rheumatoid arthritis; Rituximab

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOSPORIN A; HYDROXYCHLOROQUINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB;

ADULT; B LYMPHOCYTE; CELL SURVIVAL; COHORT ANALYSIS; DISEASE DURATION; DRUG EFFICACY; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTION; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CODON; FEMALE; HOMOZYGOTE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 84857501180     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.06.012     Document Type: Review

References (41)

1. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
2. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350(25):2572-2581.
3. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002, 46:2029-2033.
4. Cohen S.B., Emery P., Greenwald M.W., REFLEX Trial Group, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54(9):2793-2806.
5. De Vita S., Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 2006, 5(7):443-448.
6. Caporali R., Caprioli M., Bobbio-Pallavicini F., Bugatti S., Montecucco C. Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 2009, 8(7):591-594.
7. Dörner T., Isenberg D., Jayne D., Wiendl H., Zillikens D., Burmester G., International Roundtable on B cells as Therapeutic Target for Intervention Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 2009, 9(2):82-89.
8. Dörner T., Burmester G.R. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 2008, 20(3):263-268.
9. Thurlings R.M., Vos K., Wijbrandts C.A., Zwinderman A.H., Gerlag D.M., Tak P.P. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008, 67(7):917-925.
10. Teng Y.K., Levarht E.W., Hashemi M., et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007, 56(12):3909-3918.
11. Vos K., Thurlings R.M., Wijbrandts C.A., van Schaardenburg D., Gerlag D.M., Tak P.P. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56(3):772-778.
12. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010, 49(1):15-24.
13. Mima T., Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009, 21(3):224-230.
14. Fonseca J.E., Santos M.J., Canhão H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8(7):538-542.
15. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006, 8(Suppl 2):S2.
16. Rose-John S., Scheller J., Elson G., Jones S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006, 80:227-236.
17. Kallen K.J. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2002, 1592:323-343.
18. Jones S.A., Richards P.J., Scheller J., Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005, 25:241-253.
19. Panoulas V.F., Stavropoulos-Kalinoglou A., Metsios G.S., et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009, 204(1):178-183.
20. Smith A.J.P., Humphries S.E. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009, 20:43-59.
21. Fishman D., Faulds G., Jeffery R., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102(7):1369-1376.
22. Esteve E., Villuendas G., Mallolas J., et al. Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin Endocrinol (Oxf) 2006, 65(1):88-91.
23. Smith A.J., D'Aiuto F., Palmen J., et al. Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. Clin Chem 2008, 54(5):841-850.
24. Pascual M., Nieto A., Matarán L., Balsa A., Pascual-Salcedo D., Martín J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000, 1(5):338-340.
25. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(3):315-324.
26. Thurlings R.M., Vos K., Gerlag D.M., Tak P.P. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial non responders versus initial responders. Arthritis Rheum 2008, 58(12):3657-3664.
27. Quartuccio L., Fabris M., Salvin S., et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48(12):1557-1559.
28. Guzman Moreno R. B-cell depletion in autoimmune diseases. Advances in autoimmunity. Autoimmun Rev 2009, 8(7):585-590.
29. Yoshizaki K., Nishimoto N., Mihara M., Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998, 20(1-2):247-259.
30. Fabre S., Guisset C., Tatem L., et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol 2009, 155(3):395-402.
31. Reich D., Patterson N., Ramesh V., et al. Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels; Health, Aging and Body Composition (Health ABC) Study. Am J Hum Genet 2007, 80(4):716-726.
32. Galicia J.C., Tai H., Komatsu Y., Shimada Y., Akazawa K., Yoshie H. Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun 2004, 5(6):513-516.
33. Cambridge G., Isenberg D.A., Edwards J.C., et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008, 67(7):1011-1016.
34. Cambridge G., Stohl W., Leandro M.J., Migone T.S., Hilbert D.M., Edwards J.C. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006, 54(3):723-732.
35. Cornec D., Avouac J., Youinou P., Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev 2009, 8(6):515-519.
36. Nakajima K., Itoh K., Nagatani K., et al. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007, 36(5):365-372.
37. Rochas C., Hillion S., Saraux A., et al. Transmembrane BAFF from rheumatoid synoviocytes requires interleukin-6 to induce the expression of recombination-activating gene in B lymphocytes. Arthritis Rheum 2009, 60(5):1261-1271.
38. Emmerich F., Bal G., Barakat A., et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007, 136(2):309-314.
39. van Vollenhoven R.F., Chatzidionysiou K., Gabay C., et al. Rheumatoid factor predicts response to rituximab in a European registry-based cohort: 6-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA). Ann Rheum Dis 2009, 68(Suppl3):579.
40. Buch M.H. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2010, 22(3):321-329.
41. Senolt L., Vencovský J., Pavelka K., Ospelt C., Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev 2009, 9(2):102-107.